Related Experiment Video

Updated: Jun 11, 2026

The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
09:26

The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse

Published on: May 16, 2016

Protease-activated receptor 2: a novel pathogenic pathway in a murine model of osteoarthritis

William R Ferrell1, Elizabeth B Kelso, John C Lockhart

  • 1University of Glasgow, UK. W.Ferrell@bio.gla.ac.uk

Annals of the Rheumatic Diseases
|June 30, 2010
PubMed
Abstract

Insights

Protease-activated receptor 2 (PAR-2) drives osteoarthritis progression. Inhibiting PAR-2 in mice significantly reduced cartilage erosion and bone changes, highlighting PAR-2 as a therapeutic target for osteoarthritis.

Area of Science:

  • Biomedical Science
  • Orthopedics
  • Molecular Biology

Background:

  • Osteoarthritis (OA) is a debilitating global health issue.
  • Current treatments for OA lack disease-modifying capabilities.
  • Novel therapeutic targets are urgently needed for OA management.

Purpose of the Study:

  • To investigate the role of protease-activated receptor 2 (PAR-2) in osteoarthritis pathogenesis.
  • To evaluate PAR-2 as a potential therapeutic target for osteoarthritis.

Main Methods:

  • Experimental osteoarthritis was induced in wild-type and PAR-2-deficient mice via medial meniscotibial ligament (MMTL) sectioning.
  • Cartilage degradation and subchondral bone formation were assessed as OA pathology indicators.
  • PAR-2 was inhibited therapeutically in wild-type mice using a PAR-2 antagonist and a monoclonal antibody.

Main Results:

  • PAR-2-deficient mice exhibited substantially reduced cartilage erosion and subchondral bone formation compared to wild-type mice.
  • Therapeutic inhibition of PAR-2 in wild-type mice effectively reduced OA progression.
  • PAR-2 was upregulated in chondrocytes of mice with induced osteoarthritis.
  • PAR-2 deficiency provided sustained protection against joint degradation over 8 weeks.

Conclusions:

  • PAR-2 plays a critical role in the development and progression of osteoarthritis.
  • Targeting PAR-2 demonstrates significant therapeutic potential for treating osteoarthritis.
  • These findings provide proof of concept for developing PAR-2-based osteoarthritis therapies.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...